Inventors:
David P. Arnott - San Mateo CA, US
Austin L. Gumey - Belmont CA, US
Philip E. Hass - Moss Beach CA, US
James M. Lee - San Bruno CA, US
Yan Wu - Foster City CA, US
International Classification:
A61K 38/20
C12N 15/63
C12N 5/10
C12N 1/21
C12N 1/16
C07K 14/54
A61K 39/395
G01N 33/53
C12Q 1/02
C12Q 1/68
C12N 5/078
C12P 21/00
A61P 37/02
B65D 90/00
C07H 21/04
US Classification:
424 852, 536 235, 4353201, 435358, 43525233, 4352542, 435348, 435 6952, 530351, 4241581, 5303892, 5303881, 5303873, 436501, 435 29, 435 61, 435375, 435 696, 2064595
Abstract:
The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.